The key market players in the cytokine market includes Novartis, Pfizer, Sanofi, AbbVie Inc, UCB S.A, F. Hoffmann-La Roche Ltd, Merck KgaA, Lonza Group Ltd, Abcam plc., Genscript Biotech Corporation, and Randox Laboratories Ltd., among others.
The global cytokine market is expected to grow in the forecast period of 2022-2027 at a CAGR of 6%.
Cytokines are molecular messengers that allow immune system cells to communicate with one another to produce a coordinated, powerful, yet self-contained response to a specific antigen. Increased efforts to identify cytokines and utilise their enormous signalling networks to develop cancer treatments have mirrored the increased interest in leveraging the immune system to eradicate cancer over the last two decades. They increase tumour cell identification by cytotoxic effector cells by directly stimulating immunological effector cells and stromal cells at the tumour site. Cytokines are finding wider usage in cancer therapy over the world.
In cancer pathogenesis, the mix of cytokines produced in the tumour microenvironment is critical. Cancer formation and progression can be slowed by cytokines generated in response to infection, inflammation, and immunity. Cancer cells, on the other hand, can respond to cytokines produced by the host, which stimulate proliferation, suppress apoptosis, and aid invasion and metastasis.
Moreover, its demand is expected to rise as Cancer Research in United Kingdom suggests that the number of cancer cases is expected to increase across the world in the future. According to the report, if recent trends in the incidence of significant cancers and population growth are consistent, there will be 27.5 million new cancer cases worldwide each year by 2040 compared to 17 million in 2018.
North America is dominating the market presently due to the increasing prevalence of cancer in the region. As per the American Cancer Society, there was an estimate of 1,762,450 new cases diagnosed and 606,880 deaths in the United States, and the numbers are expected to rise in the future. Growth in the research and development of this therapy, along with much lesser side effects (as compared to chemotherapy), has predisposed cytokine therapy, a non-specific immunotherapy. This factor has raised the market share of cytokines in the United States among cancer therapies.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. As a leading global medicines company, the company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125, 000 people of more than 140 nationalities work at Novartis around the world.
|Headquarters:||New York, United States|
Pfizer is a leading research-based biopharmaceutical company. The company applies science and global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of the time.
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 is the world's fifth largest by prescription sales. Sanofi is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. It provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of ambitions.
|Headquarters:||Lake Bluff, Illinois, United States|
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. Its mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The company strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health, and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. With more than 8500 employees in approximately 40 countries, the company invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.